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Abstract
Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, es-
pecially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted
yet.
Objectives: This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR),
sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014.
Methods: A Markov micro-simulation model was used to evaluate the cost-effectiveness of the three drug strategies for a cohort
of 10000 patients. Quality-adjusted life-years (QALYs) were extracted from published studies. Cost data was estimated through the
review of medical records and obtaining experts opinion.
Results: The results showed that the SOF + PR drug compared with PR had a lower cost and was more effective, but compared with
the LDV/SOF, in spite of its lower cost, it was less efficient. The QALY values obtained for PR, SOF + PR and LDV/SOF, respectively, were
10.98, 12.08 and 12.28 and their costs were $ 41,741, $ 7,676 and $ 46,993. Moreover, the results obtained from acceptability curves
showed that SOF + PR were the most cost-effective treatment for thresholds below $ 45,270 PPP.
Conclusions: The use of SOF + PR regimen or LDV/SOF can significantly reduce the incidence of complications associated with the
disease. For example, short and long-term outcomes are better than the current drug regimens for HCV genotype 1 patients in all
stages of the disease.
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1. Background
Hepatitis C can incessantly have a substantial impact
on the health system with an increasing burden being ex-
pected in the next decade due to related mortality, mor-
bidity, and liver transplantation (1). Early treatments of
chronic HCV can considerably decrease the risk of develop-
ing advanced liver disease such as cirrhosis and liver can-
cer, decrease mortality and thus reduce the related costs
(2-4).
Treatment of chronic HCV infection, with PR as the pre-
vious standard of care, is lengthy (24 to 48 weeks) and toxic
with moderate efficacy. This treatment can result in sus-
tained virological response (SVR) in about 80% of people
with genotypes 2 and 3 and about 40% - 50% of people with
genotype 1 (5, 6).
However, the treatment of chronic HCV infection is
rapidly improving (7-11). The new regimens are highly ef-
ficacious (> 90% SVR), have reduced the duration of treat-
ment (8 to 12 weeks) and have minimal side effects (12),
which resulted in improving the patients’ quality of life
(6). The high price of the new regimens is the main factor
limiting their use in many countries.
It is estimated that about 187,000 people with chronic
HCV infection live in Iran with more than 50% of them be-
ing infected with genotype 1 (13).
Since SOF is a new drug, there are not many economic
evaluation studies on the drug throughout the world.
However, the results of a few conducted studies suggests
that compared with current treatments for HCV genotype
1, the SOF + PR or LDV/SOF drug regimens can be associated
with more favorable short-term and long-term health and
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economic outcomes at all levels and stages of the disease
and they can be considered as a more cost effective option,
especially for genotype 1 (14, 15). Several economic evalua-
tion studies on the treatment of CHC have been conducted
and published in America and Europe. However, in the
Eastern Mediterranean region (EMRO), particularly Iran,
there is no published study using economic evaluation
models for the study of drug therapy protocols in patients
with hepatitis C. Thus, because of the lower rate of im-
provement in patients with HCV genotype 1, it is necessary
to carry out an economic evaluation study to determine
the most cost effective strategy amongst the three strate-
gies of PR, SOF+ PR and SOF/LDV. Therefore, this study is
aimed to assess the cost-utility of patients with HCV geno-
type 1 from the perspective of payers and determine the
most appropriate drug treatment protocols for this group
of patients with regards to cost-utility and economic con-
siderations in the country.
2. Objectives
This study is aimed to assess the cost-effectiveness of
three drug regimens of pegylated interferon and ribavirin
(PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir
(LDV/SOF) in patients with HCV genotype 1 in Iran in the
year 2014.
3. Methods
3.1. Model Overview
In this study, we conducted a cost-utility analysis of
three drug therapy strategies including PR, SOF + PR and
SOF/LDV, which are used for patients with HCV genotype
1. Due to the chronic and recursive nature of HCV infec-
tion, the analysis was carried out using the Markov model.
The outcome used in this model included QALYs, the costs
spent on each health state and each treatment strategy.
The scope of the study was the payer; therefore, direct med-
ical and non-medical costs were investigated. The time
horizon of the study was the patients’ lifetime and the
time interval was one year. For every one year time inter-
val in the model the patients remained at their current
state or moved to other health states such as SVR with com-
pensated cirrhosis, SVR without CC, compensated cirrhosis
(CC), decompensated cirrhosis (DC), hepatocellular carci-
noma (HCC), liver transplant and death. For the nature of
changes in disease states to be consistent with other pub-
lished cost-utility studies (14-17) and to follow the opinions
of experts, the time interval was selected to be one-year cy-
cle. Since the time horizon was more than one year, the
economic and clinical outcomes were discounted with an
annual rate of 7.2% (18) and 3% (19, 20). The mentioned dis-
count rates have been previously used by other published
economic evaluation studies in Iran (20). The analysis was
carried out using Tree Age 2011 software.
3.2. Patient Population
Because of the lack of evidence in the country regard-
ing the two regimens SOF+PR and SOF/LDV, we used infor-
mation including effectiveness and transition probability
taken from studies published in other countries. How-
ever, data on patients using PR was collected from 144 pro-
files registered by the research center of gastroenterology
and hepatology in Baqiyatallah University. Approximately
78% of these patients did not have cirrhosis (score F0- F3)
and 22% did (score F4) all with a mean age of 50 years.
This is consistent with the reported proportion of HCV pa-
tients with cirrhosis in Iran, which is approximately 20%
(21). These centers are national referral centers and pa-
tients from all over the country are admitted to there for
treatment. Micro-simulation analysis was carried out for a
cohort hypothetical population of 10000 people.
Patients who were infected with CHC and diagnosed by
biopsy or Fibro Sca were entered into the study.
3.3. Switching Drugs
In this study, if patients had no response, showed drug
resistance or showed side effects due to initial drug ther-
apy regimens their drugs were switched. Nowadays, com-
binations of PR regimens are used for treating patients
with HCV genotype 1. According to the published studies,
in this group of patients, the response rate to this drug reg-
imen is only 40% - 50% (5, 22), which requires the patients
who do not respond to the treatment to use a new drug
regimen. Recently, two drug regimens, i.e. SOF + PR and
SOF/LDV, have been introduced in the country and accord-
ing to the published evidence the response rate for these
drugs in patients with HCV genotype 1 is more than 90%
(23, 24). Therefore, for patients who had no response to the
current treatment regimen, a switch to a new drug regi-
men was used and a new state called withdrawal was added
to the model.
3.4. Model Structure
Figure 1 shows a schematic diagram of the Markov
model for a simulated population of 10000 CHC patients.
As indicated by the diagram, CHC patients who are taking
the drug can undergo a transition in a reciprocating state.
The intended states and their changes were determined
and utilized based on the evidence found in the published
studies and the opinions of experts. Patients with different
health states and are undergoing treatment can face HCC
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and death. Those with chronic hepatitis C infection were
entered into the Markov model as the initial distribution.
The designed Markov model compared the three drug
therapy strategies and the patients who were evaluated by
the model received one of the three drug regimens (see Fig-
ure 1).
3.5. Model Assumptions
- According to the available clinical evidence, the re-
sponse rate for SOF + PR and SOF/LDV is assumed to be 100%.
- The SVR state in the model is assumed as the goal of
treatment and as the cure state.
- It is assumed that patients who reach the SVR state in
METAVIR fibrosis score F0 - F2 are left in this state and do
not experience the progress of the disease until death.
- It is assumed that patients who reach the SVR state in
METAVIR fibrosis score F3 - F4 are possibly less exposed to
the risk of developing liver disease than those who do not
reach SVR state.
- It is assumed that patients who do not reach the SVR
state are at risk of the progress of liver disease.
- The probabilities for some transitions were only avail-
able for some drugs. In such cases, regardless of the drug,
it was assumed that all treated patients had equal chances
of improvement or progression of the disease.
3.6. Transitional Probabilities
Transitional probabilities of parameters used in the
model are presented in Table 1. Due to the lack of evidence
in the country, especially clinical data about the new drug
regimens administered for patients with chronic hepatitis
C, most of the transitional probabilities of different health
states were extracted from the published studies which
were solely focusing on this issue (4, 25-32).
To include the cause of death other than HCV, we used
the probabilities of life tabulation 2012 by age and sex. The
probabilities of HCV related deaths were extracted from
the published studies (4, 14, 15, 25-32). Some other proba-
bilities were also extracted through assessing the registry
of patients in the studied centers.
As a number of articles had reported the data on clin-
ical efficacy by rate, we first changed the rates into proba-
bilities using the following formula (33) and then included
them in the model.
Equation 1.
(1)P = 1− exp(−rt)
Where P, probability; r, rate; t, time.
3.7. Health Outcomes
In this study, QALY was considered as the health out-
come. The utility values used in the model are presented
in Table 1. Since the two drug regimens of SOF + PR and
SOF/LDV are recently introduced and used in the country,
there is a lack of sufficient evidence determining the values
used in the model, we used the evidence found in studies
published in other countries (14-17, 34).
3.8. Cost Inputs
The data on direct medical costs on different states of
CHC and other complications associated with the disease
such as CC, DC and HCC were extracted from outpatient
and inpatient medical records in the mentioned treatment
centers and the self-reports of specialists. For each disease
state there was an attempt to collect data on direct medi-
cal costs including the average number of physician visits,
prescribed medicines, diagnostic services, treatment and
hospitalization and use of other services.
Resources used to calculate the costs were based on
prices from 2014. To make international comparisons we
tried to convert the costs to international dollars using the
purchasing power parity (PPP) with an exchange rate of
8565.41 Rials per $ 1 (35). The cost of each health state is pre-
sented separately in Table 1 with the cost details shown in
Table 2.
3.9. Cost-Effectiveness Analysis
Based on the results obtained from the previous stages,
a Markov model was applied using the Tree age software
and the collected data was included into the model. Tak-
ing into account the time horizon of the study, we calcu-
lated the costs, effectiveness and cost-effectiveness for all
interventions with monetary units. QALY, Cost per QALY
and their ICERs were obtained using the following formula
(36).
(2)ICER =
CostA− CostB
OutcomeA−OutcomeB
Where A, SOF/LDV; B, other antiviral.
3.10. Sensitivity Analysis
To measure the level of certainty in base-case results,
a probabilistic sensitivity analysis (PSA) was performed on
the results of the model. Therefore, with regards to the
defined probability distributions for the parameters that
were entered into the model, a second-order Monte Carlo
simulation model was conducted using 5000 trials to ana-
lyze the probabilistic sensitivity. PSA results are presented
using the cost-effectiveness acceptability curves and incre-
mental cost-effectiveness scatter plot. In this article, the
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Table 1. Input Parameters Used in Economic Model: HCV
Variable Mean Distribution SD Alpha Beta
Prob CHC to W_pr 0.55 Beta 0.2258 2.67 2.18
Prob CHC to SVR_pr 0.45 Beta 0.2258 2.18 2.67
Prob CHC to CC 0.115 Beta 0.04106 6.94 53.43
Prob CHC to HCC 0.011 Beta 0.04106 0.07 6.38
Prob CC to W_pr 0.55 Beta 0.23868 2.39 1.96
Prob CC to SVR_pr 0.33 Beta 0.23868 1.28 2.60
Prob CC to DC 0.039 Beta 0.04106 0.87 21.36
Prob CC to HCC 0.024 Beta 0.04106 0.33 13.56
Prob DC to LT 0.031 Beta 0.04106 0.55 17.27
Prob LT to Death 0.107 Beta 0.04106 6.06 50.61
Prob DC to HCC 0.014 Beta 0.04106 0.11 8.07
Prob CHC to SVR_ls 0.977 Beta 0.2258 0.43 0.01
Prob CC to SVR_ls 0.96 Beta 0.23868 0.65 0.03
Prob CHC to SVR_spr 0.91 Beta 0.2258 1.46 0.14
Prob CC to SVR_spr 0.79 Beta 0.23868 2.30 0.61
Utility CHC_pr 0.6657 Beta 0.085 20.50 10.30
Utility CHC_spr 0.645 Beta 0.085 20.44 11.25
Utility CHC_sl 0.835 Beta 0.085 15.92 3.15
Utility CC_pr 0.6257 Beta 0.085 20.28 12.13
Utility CC_spr 0.605 Beta 0.085 20.01 13.07
Utility CC_sl 0.795 Beta 0.085 17.93 4.62
Utility DC 0.525 Beta 0.08957 16.32 14.76
Utility DC_spr 0.525 Beta 0.08957 16.32 14.76
Utility DC_sl 0.715 Beta 0.08957 18.16 7.24
Utility HCC 0.465 Beta 0.08957 14.42 16.59
Utility HCC_spr 0.465 Beta 0.08957 14.42 16.59
Utility HCC_sl 0.655 Beta 0.08957 18.45 9.72
Cost CHC_sl 86208 Gamma 34152 6.37 0.00
Cost CHC_spr 11903 Gamma 34152 0.12 0.00
Cost CHC_pr 15772 Gamma 34152 0.21 0.00
Cost CC_sl 86664 Gamma 34035 6.48 0.00
Cost CC_spr 12359 Gamma 34035 0.13 0.00
Cost CC_pr 16771 Gamma 34035 0.24 0.00
Cost DC_sl 101124 Gamma 33796 8.95 0.00
Cost DC_spr 36862 Gamma 33796 1.19 0.00
Cost DC_pr 23798 Gamma 33796 0.50 0.00
Cost HCC_sl 112023 Gamma 31208 12.88 0.00
Cost HCC_spr 52508 Gamma 31208 2.83 0.00
Cost HCC_pr 40718 Gamma 31208 1.70 0.00
Prob HCC to LT 0.0003 Beta 0.04106 0.00 0.18
Prob CHC to SVR_pr_spr 0.72 Beta 0.2258 2.85 1.11
Prob CC to SVR_pr_spr 0.62 Beta 0.23868 2.56 1.57
Prob CHC to SVR_pr_ls 0.79 Beta 0.2258 2.57 0.68
Prob CC to SVR_pr_ls 0.8 Beta 0.23868 2.25 0.56
Abbreviations: Prob, probability; CC, compensated cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; SVR, sustained virological response; LT, liver transplantation; W, withdrawal; pr, pegylated interferon and
ribavirin; spr, sofosbuvir + pegylated interferon and ribavirin; sl, ledipasvir and sofosbuvir; SD, standard deviation, Alpha and Beta are the distribution kind of mentioned variables.
PSA results are characterized with the use of incremen-
tal cost-effectiveness, scatter plot and cost-effectiveness ac-
ceptability curves. Due to the lack of WTP threshold in Iran
the WTP per every QALY, based on the WHO’s approach was
considered as one to three times of gross domestic prod-
uct per capita. In 2014, it was 4670 dollars per capita (37).
Meanwhile, due to international comparison, we used the
latest gross domestic product per capita based on the pur-
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Table 2. Results of Drug Acquisition Costs Used in the Model
Treatment Unit cost, PPP $ ( Per pill)
Ribavirin 0.7
Pegylated interferon 173
Sofosbuvir 60
Ledipasvir/sofosbuvir 979
chasing power parity (PPP), which was 15090.05 US dollars
in 2013 (37, 38).
4. Results
In this study, based on the initial distribution of the
model, a total of 144 CHC patients who were 14 years of age
and were referred to the selected centers were enrolled in
the study and were classified by age, sex and duration of
the disease. The mean age of the patients was 50 years; with
79% being male and 21% female.
The results showed that SOF + PR drug, compared with
the two drug therapy strategies, was more cost effective.
When compared to the PR it had a lower cost and was more
effective but compared with the LDV/SOF, in spite of its
lower cost, it was less efficient. As a whole, of the three
above-mentioned strategies, SOF + PR was the most cost
effective strategy with the next being LDV/SOF. PR drug,
which had the highest cost and was less effective than the
other strategies, was the failed strategy (see Figure 2, Table
3).
Cost, effectiveness, incremental costs, incremental ef-
fectiveness, ICER as well as ratings were the superiority of
the three drug strategies in CHC patients. The comparison
is presented in Table 3. The findings shown in the tabula-
tion indicate that the QALYs for each of the three medicines
of PR, SOF + PR, LDV/SOF were 10.98, 12.08 and 12.28; in addi-
tion, the costs were $ 41.741, $ 7.676 and $ 46.993 As shown
and compared with other alternatives, PR and LDV/SOF had
the minimum and maximum expected effectiveness and
SOF + PR and LDV/SOF had the minimum and maximum
expected costs over the period of a life time. Furthermore,
LDV/SOF with about 190,335 dollars PPP is the highest cost
per QALY compared with the other strategies (Table 3).
4.1. Probabilistic Sensitivity Analysis (PSA)
In this study, because it was possible to measure all
the variables, they were considered to be distributed. In
this study, the distribution of beta (β) was used to deter-
mine the distribution of transitional probabilities and util-
ity values that were between 0 to 1. Additionally the gamma
distribution was used to determine the distribution of the
costs (Table 1). Thus, a second-order Monte Carlo simula-
tion using 5000 trials was conducted for the analysis of
probabilistic sensitivity. The results of the measurement
of uncertainty using cost-effectiveness acceptability curves
and incremental cost-effectiveness scatter plot (ICER) dis-
tribution curves are as follows.
The results of the acceptability curves showed that in
91.7% to 85.7% of simulations SOF + PR was the most cost
effective treatment for thresholds less than 45,270 US dol-
lars. The next best drug strategy was LDV/SOF which was
the optimal strategy in 4.4% to 12.5% of the simulations.
PR drug was the best strategy only in 3.9% to 1.8% of the
simulations (see Figure 3). Moreover, the results of the bar
graph showed that in 85.7% of simulations SOF + PR drug
in thresholds less than $ 45,270 was identified as the best
strategy while the other strategies were superior strategies
only in 14.3% of simulations (see Figure 4A - 4B).
The scatter plots provide more detailed information
for individual comparisons. The results of scatter plots are
only shown for the two superior options compared with
PR. The results of the scatter plots showed that in 92% and
32% of simulations, respectively, SOF + PR and LDV/SOF,
were located in the fourth region of the cost-effectiveness
plot. For example in a region with lower-costs and higher
effectiveness, as compared with PR, they were considered
as the superior strategies. In 2% and 58% of simulations,
they were in the first region, under the threshold. For ex-
ample in a region with higher costs and higher effective-
ness, compared with the PR. In 2% and 0% of the simula-
tions they were under the threshold at the third region.
Therefore, overall SOF + PR and LDV/SOF in 96% and 90%
of simulations were at the acceptable region, below the
threshold, as compared with the PR and as a result they de-
feated the PR strategy and were identified as the more cost
effective strategies. Moreover, SOF + PR and LDV/SOF in 4%
and 10% of the simulations were in the rejected area above
the threshold as compared with the PR and were identified
as the non-cost effective (inferior) strategies.
Therefore, the results of sensitivity analysis showed
that SOF + PR was the most effective treatment and LDV/SOF
was the subsequent treatment strategy with no change in
their status compared with the PR strategy. This indicates
that the results of this study are robust.
The results also showed that given the better effective-
ness of LDV/SOF drug strategy, if the price of the drug de-
creases from its current price, i.e. from around 980 dollars
PPP to 120 dollars PPP per each pill, then it will become the
most cost effective strategy and LDV/SOF drug will become
dominant and the other two drug strategies of SOF + PR
and PR will be totally dominated (see Figure 5). As the re-
sults of acceptability curves obtained from the sensitivity
analysis showed, in 50% to 89.7% of simulations, LDV/SOF
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Table 3. The Results of a Markov Micro-Simulation Model to Compare the Cost-Effectiveness of the Three Drug Strategies in Patients with CHC Based on the Number QALY (USD)
Strategy Cost Eff (QALY) Inc Cost Inc Eff Inc CE Rank Subset
SOF + PR 7,676 12.08 0 0 0 1 Dominant
SOF + LDV 46,993 12.28 39,316 0.21 190335 2 Dominant
PR 41,741 10.98 34,064 -1.10 -30985 3 abs. dominated
Abbreviations: Eff, Effectiveness; Inc, incremental cost; Inc Eff, incremental effectiveness, Inc CE, incremental cost-effectiveness; PR, pegylated interferon/ribavirin; SOF + PR, sofosbuvir + pegylated interferon/ribavirin; SOF + LDV, ledipasvir
+ sofosbuvir; CHC, chronic hepatitis C; QALY, quality-adjusted life-year.
was the most cost effective treatment for thresholds be-
tween 4527 to 45270 dollars PPP. SOF + PR drug was optimal
only when it was below the threshold of 4527 dollars PPP
(see Figure 6).
Figure 1. Decision Analysis Model to Evaluate the Cost-Effectiveness of Treatment
Strategies for Chronic HCV Patients
CHC CC
W
DC
LTHCCSVR
(Cure)
Death
Switching
CHC, chronic hepatitis C; CC, compensated cirrhosis; DC, decompensated cirrhosis;
HCC, hepatocellular carcinoma; SVR, sustained virological response; LT, liver trans-
plantation; W, withdrawal.
5. Discussion
Since LDV/SOF medicine is a new drug, there are a lim-
ited number of economic evaluation studies published in
the world on the drug. Hence, this study was the first eco-
nomic evaluation research on hepatitis C patients in the
country and in the EMRO region. Furthermore, it was one
of the very few studies conducted in the world, which tried
to take a pharmacoeconomic view to assess the three dif-
ferent drug therapy options for patients with HCV geno-
type 1. Therefore, this study was carried out to fulfill one of
the goals of policy decision makers to select the best drug
strategies for the inclusion in the Iran drug list (IDL). In this
study, based on the characteristics of the sample under the
study analysis, micro-simulation analysis was conducted
on CHC patients in a population of 100 thousand people.
The results showed that compared with other alterna-
tives and considering the given prices, SOF + PR was the
most cost-effective strategy. This strategy will have the
most favorable health economic outcomes in the future
compared with other strategies available for patients with
HCV and its related complications. In comparison with the
SOF + PR, although LDV/SOF drug regimen has the high-
est rate of SVR, it is not a treatment priority due to its very
high price in the country. Therefore, under a fixed budget,
more patients can successfully be treated by the SOF + PR
drug regimen as compared with other treatment alterna-
tives. In view of that, the results of this study are in line
with those of Saab et al.’s study (15). Therefore, SOF + PR
has a lower cost and is more effective than PR. Our results
are consistent with the findings of the recently published
studies, indicating that the SOF drug regimen, compared
with the other current standard drug regimens, is more ef-
fective for the treatment of HCV genotype 1 (14, 15). Also,
the results of the probability sensitivity analysis showed
that the SOF + PR drug regimen, compared with the two
other medication strategies was more cost effective and in
most simulations the obtained values were at the accepted
area and below the threshold; thus, it obtained the best re-
sults with respect to the given prices. Therefore, the results
showed that the sensitivity analysis did not change the sta-
tus of SOF + PR as the most effective drug regimen; this indi-
cates that the results of this study are robust. Accordingly,
the results of this study are in line with those of Saab et al.’s
study in the USA and Petta et al.’s study in Italy (15, 16).
The second generation of direct-acting anti-viral drugs
(all-oral) such as LDV/SOF has a high efficacy and safety.
It is also a simple treatment strategy that is free of PR
and makes great progress in improving the patients dur-
ing treatment and significantly increases SVR rate (39-41).
Therefore, the results showed that if the price of this drug
reduces, it will be the most cost effective strategy and com-
pletely dominates the other two drug regimens of SOF+PR
and PR. As the results of acceptability curves are obtained
from the sensitivity analysis indicated, LDV/SOF with its
new prices could be the most cost effective treatment in
89.7% of simulations for thresholds below 45270 dollars
PPP.
Thus, our results showed that SOF + PR or LDV/SOF drug
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Figure 2. Comparison of Cost-Effectiveness of the Three Drug Strategies in Patients With Chronic Hepatitis C Based on the Number of QALY
Peg-IFN/RBV, pegylated interferon/ribavirin; SOF + Peg-IFN/RBV, sofosbuvir + pegylated interferon/ribavirin; SOF + LDV: ledipasvir + sofosbuvir; QALY, quality-adjusted life-year.
Figure 3. Cost-Effectiveness Acceptability Curve Obtained Through Monte Carlo Simulation
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Peg-IFN/RBV, pegylated interferon/ribavirin; SOF + Peg-IFN/RBV, sofosbuvir + pegylated interferon / ribavirin; SOF + LDV, ledipasvir + sofosbuvir.
regimens could be associated with more favorable short
and long term health economic outcomes, as compared
with the current treatments for patients with HCV geno-
type 1 at all levels and stages of the disease. It can be a more
cost effective option, especially for genotype 1.
Therefore, in order to increase the rate of SVR, reduce
the treatment period, increase the quality of life of patients
and increase productivity during and after the treatment
period on one hand and to significantly reduce the risk of
complications associated with liver-disease, mortality and
the costs for patients using SOF medication regimens (6, 14,
15, 42) on the other hand, it is recommended to stop the use
of the current standard PR treatment regimen in Iran and
many other countries, as they are not recommended for
treating patients with HCV genotype 1. Therefore, a drug
with high efficiency such as SOF should be used along with
PR. Furthermore, as mentioned earlier, in the case of de-
creasing the price of the drug (LDV/SOF), it will be better to
use a PR-free drug regimen instead of the SOF + PR combi-
nation and use it as a priority for the treatment of patients.
This PR-free regimen has shown high clinical efficacy, espe-
cially in patients with HCV genotype 1 who form the major
number of HCV patients in Iran.
According to our study, to generalize the results to
other settings it is better to consider some factors such as
the availability of resources, prices, valuing outcomes by
individuals, thresholds and other indicators of the effec-
tiveness used in various studies that may affect the results
of those studies. Therefore, the generalization of the re-
sults to other settings should proceed with caution.
One of the limitations of this study was the use of some
data obtained from clinical trial studies which might dif-
fer slightly from real-world conditions. Another limita-
tion was the lack of access to patients using SOF regimen,
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Figure 4. A, B, Scatter Plot of Incremental Cost-Effectiveness of SOF+PR and SOF+LDV Compared with PR
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Figure 5. Comparison of Cost-Effectiveness of the Three Drug Strategies in Patients With Chronic Hepatitis C Based on the Number of QALY
SOF+pegIFN/ RBV
SOF+LDV
Dominated
peg-IFN/RBV
Undminated
Cost-Effectiveness Analysis
Effectiveness, QALY
C
os
t,
 U
S$
10.70    10.80    10.90   11.00   11.10     11.20     11.30    11.40     11.50   11.60     11.70    11.80    11.90    12.00    12.10   
23,000
22,000
21,000
20,000
19,000
18,000
17,000
16,000
15,000
14,000
13,000
12,000
11,000
10,000
9,000
8,000
7,000
Peg-IFN/RBV, pegylated interferon/ribavirin; SOF + Peg-IFN/RBV, sofosbuvir + pegylated interferon/ribavirin; SOF + LDV, ledipasvir + sofosbuvir; QALY, quality-adjusted life-year.
which was due to the high price of the drug in the coun-
try. Also, because of the limitations of the data required
for some simulations we had to use the constant of tran-
sitional probabilities in the model in this study.
In conclusion, based on the findings of this study, it
can be concluded that the use of SOf + PR and PR-free drug
regimens (LDV/SOF; Harvoni) in patients with HCV geno-
type 1 can reduce the side effects associated with the dis-
ease such as HCC, DC and mortality. Additionally, it can re-
duce the costs and time spent on the disease, especially if
the patient refers at early stages of the disease without cir-
rhosis and without previous experience of therapy. Even
in treatment-experienced and cirrhosis patients, the men-
tioned treatments are the most cost-effective option in the
current situation and can be used as top priority drugs.
They can also be used for switching from PR to the men-
tioned drugs.
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